Literature DB >> 30127486

The association of miR-29a with proteinuria in essential hypertension.

Yu-Qing Huang1, Cheng Huang1, Jie Li1, Bin Zhang2, Ying-Qing Feng3.   

Abstract

Recently, miRNAs have emerged as new indirect markers of inflammation that are associated with adverse outcomes in cardiovascular disease. The aim of the study was to evaluate the relationship between miR29a and proteinuria in hypertension. Fifty patients with normal albuminuria, fifty patients with micro-albuminuria, and fifty patients with macro-albuminuria were enrolled. The highest levels of miR-29a and transforming growth factor-β1 (TGF-β1) were observed in the macro-albuminuria group, followed by the micro-albuminuria and the normal albuminuria groups. The level of miR-29a was negatively correlated with the glomerular filtration rate, but was positively correlated with C-reactive protein, TGF-β1, and the urinary albumin to creatinine ratio (UACR). Circulating miR-29a was found to be significantly and independently associated with proteinuria. Our findings showed that miR-29a reflects the pathogenesis of hypertensive nephropathy and may serve as a potential non-invasive marker for detecting early stages of hypertensive nephropathy.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30127486     DOI: 10.1038/s41371-018-0097-3

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  31 in total

Review 1.  The miR-29 family: genomics, cell biology, and relevance to renal and cardiovascular injury.

Authors:  Alison J Kriegel; Yong Liu; Yi Fang; Xiaoqiang Ding; Mingyu Liang
Journal:  Physiol Genomics       Date:  2012-01-03       Impact factor: 3.107

Review 2.  Chronic kidney disease.

Authors:  Andrew S Levey; Josef Coresh
Journal:  Lancet       Date:  2011-08-15       Impact factor: 79.321

3.  Standards of medical care in diabetes--2013.

Authors: 
Journal:  Diabetes Care       Date:  2013-01       Impact factor: 19.112

Review 4.  The regulation and function of microRNAs in kidney diseases.

Authors:  Qingqing Wei; Qing-Sheng Mi; Zheng Dong
Journal:  IUBMB Life       Date:  2013-07       Impact factor: 3.885

Review 5.  Hypertensive nephropathy. Moving from classic to emerging pathogenetic mechanisms.

Authors:  Teresa M Seccia; Brasilina Caroccia; Lorenzo A Calò
Journal:  J Hypertens       Date:  2017-02       Impact factor: 4.844

Review 6.  The therapeutic potential of miRNAs regulated in settings of physiological cardiac hypertrophy.

Authors:  Jenny Y Y Ooi; Bianca C Bernardo; Julie R McMullen
Journal:  Future Med Chem       Date:  2014-02       Impact factor: 3.808

Review 7.  Diverse roles of TGF-β/Smads in renal fibrosis and inflammation.

Authors:  Hui Yao Lan
Journal:  Int J Biol Sci       Date:  2011-09-02       Impact factor: 6.580

8.  Circulating TGF-β1-Regulated miRNAs and the Risk of Rapid Progression to ESRD in Type 1 Diabetes.

Authors:  Marcus G Pezzolesi; Eiichiro Satake; Kevin P McDonnell; Melissa Major; Adam M Smiles; Andrzej S Krolewski
Journal:  Diabetes       Date:  2015-04-30       Impact factor: 9.461

9.  Higher plasma transforming growth factor (TGF)-β is associated with kidney disease in older community dwelling adults.

Authors:  Tapan Mehta; Petra Buzkova; Jorge R Kizer; Luc Djousse; Michel Chonchol; Kenneth J Mukamal; Michael Shlipak; Joachim H Ix; Diana Jalal
Journal:  BMC Nephrol       Date:  2017-03-21       Impact factor: 2.388

10.  Canonical transforming growth factor-β signaling regulates disintegrin metalloprotease expression in experimental renal fibrosis via miR-29.

Authors:  Vasudev Ramdas; Martin McBride; Laura Denby; Andrew H Baker
Journal:  Am J Pathol       Date:  2013-10-06       Impact factor: 4.307

View more
  1 in total

Review 1.  Impact of Nutritional Epigenetics in Essential Hypertension: Targeting microRNAs in the Gut-Liver Axis.

Authors:  Johnathan Kawika Cooper; Rochell Issa; Pratyush Pavan Devarasetty; Rachel M Golonka; Veda Gokula; Joshua Busken; Jasenka Zubcevic; Jennifer Hill; Matam Vijay-Kumar; Bindu Menon; Bina Joe
Journal:  Curr Hypertens Rep       Date:  2021-05-07       Impact factor: 5.369

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.